Kamaria T. Jacobs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kamaria T. Jacobs has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Clyde Brown
Institute of Public Health, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, Florida
19 shared publications - Estelamari Rodriguez
Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables, FL
19 shared publications - Gilberto Lopes
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
19 shared publications - Heidy N. Medina
University of Miami Miller School of Medicine 1 Miami, Florida
19 shared publications - Paulo S. Pinheiro
Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA
19 shared publications - Qinran Liu
American Cancer Society 1 Department of Surveillance, Prevention and Health Services Research Atlanta, Georgia
19 shared publications
Latest Publications
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S6 shows the determinants of receipt of curative-intent surgery and receipt of any curative-intent treatment in Hispanic subgroups in Florida from 2005 to 2017.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S6 shows the determinants of receipt of curative-intent surgery and receipt of any curative-intent treatment in Hispanic subgroups in Florida from 2005 to 2017.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Data from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Background:Despite the increasing adoption of stereotactic body radiotherapy (SBRT) as a recommended alternative for early-stage non–small cell lung cancer (NSCLC), population-based research on racial/ethnic disparities in curative-intent treatment accounting for SBRT remains limited. This study investigated trends and disparities in receiving curative-intent surgery and/or SBRT in a diverse, retrospective cohort.Methods:Early-stage NSCLC cases (2005–2017) from the Florida cancer registry were linked to individual-level statewide discharge data containing comorbidities and specific treatment information. Joinpoint regression assessed trends in treatment receipt. Multivariable logistic regression examined associations between race/ethnicity and treatment type.Results:Among 64,999 patients with early-stage NSCLC, 71.6% received curative-intent treatment (surgery and/or SBRT): 73.1%, 72.4%, and 60.3% among Hispanic, White, and Black patients, respectively (P < 0.01). SBRT use increased steeply from 2005 to 2007 and then by 7.9% annually from 2007 to 2017 (P < 0.01); curative-intent surgery remained stable from 2005 to 2014 before declining by 6.2% annually during 2014–2017 (P = 0.04). The Black-White disparity in receipt of curative-intent treatment was significant [ORadj, 0.65; 95% confidence interval (CI), 0.60–0.71]. Patients with Charlson comorbidity index (CCI)≥3 had 36% (ORadj, 0.64; 95% CI, 0.60–0.69) lower odds of receiving curative-intent surgery and no significant difference for SBRT (ORadj, 1.06; 95% CI, 0.93–1.20) compared with CCI = 0.Conclusions:Racial disparities in receiving curative-intent treatment for early-stage NSCLC persist despite the availability of SBRT, suggesting the full potential of curative-intent treatment for early-stage NSCLC remains unachieved.Impact:Addressing disparities in early-stage NSCLC requires addressing differential treatment patterns and enhancing accessibility to treatments like underutilized SBRT, particularly for high-comorbidity populations such as Black patients.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Background:Despite the increasing adoption of stereotactic body radiotherapy (SBRT) as a recommended alternative for early-stage non–small cell lung cancer (NSCLC), population-based research on racial/ethnic disparities in curative-intent treatment accounting for SBRT remains limited. This study investigated trends and disparities in receiving curative-intent surgery and/or SBRT in a diverse, retrospective cohort.Methods:Early-stage NSCLC cases (2005–2017) from the Florida cancer registry were linked to individual-level statewide discharge data containing comorbidities and specific treatment information. Joinpoint regression assessed trends in treatment receipt. Multivariable logistic regression examined associations between race/ethnicity and treatment type.Results:Among 64,999 patients with early-stage NSCLC, 71.6% received curative-intent treatment (surgery and/or SBRT): 73.1%, 72.4%, and 60.3% among Hispanic, White, and Black patients, respectively (P < 0.01). SBRT use increased steeply from 2005 to 2007 and then by 7.9% annually from 2007 to 2017 (P < 0.01); curative-intent surgery remained stable from 2005 to 2014 before declining by 6.2% annually during 2014–2017 (P = 0.04). The Black-White disparity in receipt of curative-intent treatment was significant [ORadj, 0.65; 95% confidence interval (CI), 0.60–0.71]. Patients with Charlson comorbidity index (CCI)≥3 had 36% (ORadj, 0.64; 95% CI, 0.60–0.69) lower odds of receiving curative-intent surgery and no significant difference for SBRT (ORadj, 1.06; 95% CI, 0.93–1.20) compared with CCI = 0.Conclusions:Racial disparities in receiving curative-intent treatment for early-stage NSCLC persist despite the availability of SBRT, suggesting the full potential of curative-intent treatment for early-stage NSCLC remains unachieved.Impact:Addressing disparities in early-stage NSCLC requires addressing differential treatment patterns and enhancing accessibility to treatments like underutilized SBRT, particularly for high-comorbidity populations such as Black patients.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Data from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Background:Despite the increasing adoption of stereotactic body radiotherapy (SBRT) as a recommended alternative for early-stage non–small cell lung cancer (NSCLC), population-based research on racial/ethnic disparities in curative-intent treatment accounting for SBRT remains limited. This study investigated trends and disparities in receiving curative-intent surgery and/or SBRT in a diverse, retrospective cohort.Methods:Early-stage NSCLC cases (2005–2017) from the Florida cancer registry were linked to individual-level statewide discharge data containing comorbidities and specific treatment information. Joinpoint regression assessed trends in treatment receipt. Multivariable logistic regression examined associations between race/ethnicity and treatment type.Results:Among 64,999 patients with early-stage NSCLC, 71.6% received curative-intent treatment (surgery and/or SBRT): 73.1%, 72.4%, and 60.3% among Hispanic, White, and Black patients, respectively (P < 0.01). SBRT use increased steeply from 2005 to 2007 and then by 7.9% annually from 2007 to 2017 (P < 0.01); curative-intent surgery remained stable from 2005 to 2014 before declining by 6.2% annually during 2014–2017 (P = 0.04). The Black-White disparity in receipt of curative-intent treatment was significant [ORadj, 0.65; 95% confidence interval (CI), 0.60–0.71]. Patients with Charlson comorbidity index (CCI)≥3 had 36% (ORadj, 0.64; 95% CI, 0.60–0.69) lower odds of receiving curative-intent surgery and no significant difference for SBRT (ORadj, 1.06; 95% CI, 0.93–1.20) compared with CCI = 0.Conclusions:Racial disparities in receiving curative-intent treatment for early-stage NSCLC persist despite the availability of SBRT, suggesting the full potential of curative-intent treatment for early-stage NSCLC remains unachieved.Impact:Addressing disparities in early-stage NSCLC requires addressing differential treatment patterns and enhancing accessibility to treatments like underutilized SBRT, particularly for high-comorbidity populations such as Black patients.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Background:Despite the increasing adoption of stereotactic body radiotherapy (SBRT) as a recommended alternative for early-stage non–small cell lung cancer (NSCLC), population-based research on racial/ethnic disparities in curative-intent treatment accounting for SBRT remains limited. This study investigated trends and disparities in receiving curative-intent surgery and/or SBRT in a diverse, retrospective cohort.Methods:Early-stage NSCLC cases (2005–2017) from the Florida cancer registry were linked to individual-level statewide discharge data containing comorbidities and specific treatment information. Joinpoint regression assessed trends in treatment receipt. Multivariable logistic regression examined associations between race/ethnicity and treatment type.Results:Among 64,999 patients with early-stage NSCLC, 71.6% received curative-intent treatment (surgery and/or SBRT): 73.1%, 72.4%, and 60.3% among Hispanic, White, and Black patients, respectively (P < 0.01). SBRT use increased steeply from 2005 to 2007 and then by 7.9% annually from 2007 to 2017 (P < 0.01); curative-intent surgery remained stable from 2005 to 2014 before declining by 6.2% annually during 2014–2017 (P = 0.04). The Black-White disparity in receipt of curative-intent treatment was significant [ORadj, 0.65; 95% confidence interval (CI), 0.60–0.71]. Patients with Charlson comorbidity index (CCI)≥3 had 36% (ORadj, 0.64; 95% CI, 0.60–0.69) lower odds of receiving curative-intent surgery and no significant difference for SBRT (ORadj, 1.06; 95% CI, 0.93–1.20) compared with CCI = 0.Conclusions:Racial disparities in receiving curative-intent treatment for early-stage NSCLC persist despite the availability of SBRT, suggesting the full potential of curative-intent treatment for early-stage NSCLC remains unachieved.Impact:Addressing disparities in early-stage NSCLC requires addressing differential treatment patterns and enhancing accessibility to treatments like underutilized SBRT, particularly for high-comorbidity populations such as Black patients.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S5 shows the stratification analyses of receipt of curative-intent surgery and receipt of any curative-intent treatment by region in Florida from 2005 to 2017.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S5 shows the stratification analyses of receipt of curative-intent surgery and receipt of any curative-intent treatment by region in Florida from 2005 to 2017.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S1 shows the specific weights and codes used in the NCI Comorbidity Index.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S1 shows the specific weights and codes used in the NCI Comorbidity Index.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S8 shows the sensitivity analyses of receipt of curative-intent surgery and receipt of any curative-intent treatment by excluding T3 and possible stage IIB node-positive cases in Florida from 2005 to 2017.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S8 shows the sensitivity analyses of receipt of curative-intent surgery and receipt of any curative-intent treatment by excluding T3 and possible stage IIB node-positive cases in Florida from 2005 to 2017.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S7 shows the determinants of receipt of curative-intent surgery and receipt of any curative-intent treatment with adjustment for measures of geographical proximity to major healthcare centers in Florida from 2005 to 2017.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S7 shows the determinants of receipt of curative-intent surgery and receipt of any curative-intent treatment with adjustment for measures of geographical proximity to major healthcare centers in Florida from 2005 to 2017.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S8 shows the sensitivity analyses of receipt of curative-intent surgery and receipt of any curative-intent treatment by excluding T3 and possible stage IIB node-positive cases in Florida from 2005 to 2017.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S8 shows the sensitivity analyses of receipt of curative-intent surgery and receipt of any curative-intent treatment by excluding T3 and possible stage IIB node-positive cases in Florida from 2005 to 2017.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S4 shows the full list of determinants of receipt of curative surgery and any curative-intent treatment in Florida from 2005 to 2017.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S4 shows the full list of determinants of receipt of curative surgery and any curative-intent treatment in Florida from 2005 to 2017.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S5 shows the stratification analyses of receipt of curative-intent surgery and receipt of any curative-intent treatment by region in Florida from 2005 to 2017.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Supplementary Table S5 shows the stratification analyses of receipt of curative-intent surgery and receipt of any curative-intent treatment by region in Florida from 2005 to 2017.